Opioid Induced Constipation Treatment Market size|share|Research|Trends|forecast to 2026
Global Opioid-Induced Constipation Treatment Market is estimated to reach USD 5 billion by 2026.
(EMAILWIRE.COM, October 24, 2019 ) Market Overview
• Opioid-induced constipation (OIC) is a type of secondary illness associated with prolonged use of opioids. Approximately 40%-80% of patients receiving opioid analgesic may experience OIC.
Market Dynamics
• The market is primarily driven by an expanding the base of OIC sufferers as a result of increased use of opioids in the treatment of chronic pain.
• The global burden of chronic pain is significant and growing with over 1.5 billion people suffering from it. However, lack of awareness about opioid-induced constipation in patients is likely to limit the market growth.
• Also, there is a vast unmet need in the market for highly-targeted, safe and efficient therapeutic options for OIC management.
• Traditional first-line approaches to treating OIC such as laxatives have limited efficacy. OIC can be chronic and may be unresponsive to common laxative treatment regimens.
Market Segmentation
• Opioid-Induced Constipation Treatment market report segments the market by drug class, by the method of administration, by distribution channel, and by region.
• Based on drug class, the OIC treatment market is categorized into Mu- Opioid Receptor Antagonist, Locally Acting Chloride Channel Activator, Peripherally-Restricted Mu-opioid Receptor Antagonist, and Non-selective Opioid Antagonist.
• Mu-opioid Receptor Antagonists segment is likely to overtake chloride channel activators by 2025 regarding market share and revenue generation due to its higher efficacy compared to other drugs.
• Based on the mode of administration, the market is segmented into oral and parenteral.
• Based on the distribution channel, the market is segmented into a drug store, independent pharmacies, and hospital pharmacies.
Key Segments Covered in the report
By Drug Class
• Mu-Opioid Receptor Antagonist
• Locally Acting Chloride Channel Activator
• Peripherally-Restricted Mu-opioid Receptor Antagonist
• Non-selective Opioid Antagonist
By Mode of Administration
• Oral
• bowel movements
• Parenteral
• abdominal pain
By Distribution Channel
• Hospital Pharmacies
• Independent Pharmacies
• Drug stores
Geographical Analysis
• Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
• Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
• North America (The USA, Canada, Mexico)
• South America (Brazil, Argentina, Rest of South America)
• Rest of the World
Company Profiles
The report also profiles the following companies in Opioid-Induced Constipation Treatment market – GlaxoSmithKline, Inc., AstraZeneca plc, Inc., Pfizer, Inc., S.L.A. Pharma AG, AIKO Biotechnology, Cubist Pharmaceuticals, Salix Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited.
View full sample report: https://www.datamintelligence.com/research-report/opioid-induced-constipation-treatment-market
Download free sample: https://www.datamintelligence.com/download-sample/opioid-induced-constipation-treatment-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
• Opioid-induced constipation (OIC) is a type of secondary illness associated with prolonged use of opioids. Approximately 40%-80% of patients receiving opioid analgesic may experience OIC.
Market Dynamics
• The market is primarily driven by an expanding the base of OIC sufferers as a result of increased use of opioids in the treatment of chronic pain.
• The global burden of chronic pain is significant and growing with over 1.5 billion people suffering from it. However, lack of awareness about opioid-induced constipation in patients is likely to limit the market growth.
• Also, there is a vast unmet need in the market for highly-targeted, safe and efficient therapeutic options for OIC management.
• Traditional first-line approaches to treating OIC such as laxatives have limited efficacy. OIC can be chronic and may be unresponsive to common laxative treatment regimens.
Market Segmentation
• Opioid-Induced Constipation Treatment market report segments the market by drug class, by the method of administration, by distribution channel, and by region.
• Based on drug class, the OIC treatment market is categorized into Mu- Opioid Receptor Antagonist, Locally Acting Chloride Channel Activator, Peripherally-Restricted Mu-opioid Receptor Antagonist, and Non-selective Opioid Antagonist.
• Mu-opioid Receptor Antagonists segment is likely to overtake chloride channel activators by 2025 regarding market share and revenue generation due to its higher efficacy compared to other drugs.
• Based on the mode of administration, the market is segmented into oral and parenteral.
• Based on the distribution channel, the market is segmented into a drug store, independent pharmacies, and hospital pharmacies.
Key Segments Covered in the report
By Drug Class
• Mu-Opioid Receptor Antagonist
• Locally Acting Chloride Channel Activator
• Peripherally-Restricted Mu-opioid Receptor Antagonist
• Non-selective Opioid Antagonist
By Mode of Administration
• Oral
• bowel movements
• Parenteral
• abdominal pain
By Distribution Channel
• Hospital Pharmacies
• Independent Pharmacies
• Drug stores
Geographical Analysis
• Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)
• Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)
• North America (The USA, Canada, Mexico)
• South America (Brazil, Argentina, Rest of South America)
• Rest of the World
Company Profiles
The report also profiles the following companies in Opioid-Induced Constipation Treatment market – GlaxoSmithKline, Inc., AstraZeneca plc, Inc., Pfizer, Inc., S.L.A. Pharma AG, AIKO Biotechnology, Cubist Pharmaceuticals, Salix Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited.
View full sample report: https://www.datamintelligence.com/research-report/opioid-induced-constipation-treatment-market
Download free sample: https://www.datamintelligence.com/download-sample/opioid-induced-constipation-treatment-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results